Trends in risk factors of anastomotic leakage after colorectal cancer surgery (2011–2019): A Dutch population-based study

Melissa N. N. Arron1 | Nynke G. Greijdanus1 | Richard P. G. ten Broek1 | Jan Willem T. Dekker3 | Frans van Workum4 | Harry van Goor1 | Pieter J. Tanis2 | Johannes H. W. de Wilt1

1Radboud Institute for Health Sciences, Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
2Amsterdam UMC, Department of Surgery, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands
3Department of Surgery, Reinier de Graaf Hospital, Delft, The Netherlands
4Department of Surgery, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

Correspondence
Melissa N. N. Arron, Radboud university medical centre, department of surgery, Geert Grooteplein Zuid 10 (internal post 618) 6525 GA Nijmegen, The Netherlands. Email: melissa.arron@radboudumc.nl

Abstract
Aim: Anastomotic leakage (AL) after colon cancer (CC) and rectal cancer (RC) surgery often requires reintervention. Prevalence and morbidity may change over time with evolutions in treatment strategies and changes in patient characteristics. This nationwide study aimed to evaluate changes in the incidence, risk factors and mortality from AL during the past nine years.

Methods: Data of CC and RC resections with primary anastomosis were extracted from the Dutch Colorectal Audit (2011–2019). AL was registered if requiring reintervention. Three consecutive cohorts were compared using logistic regression analysis.

Results: Incidence of AL after CC surgery decreased from 6.6% in 2011–2013 to 4.8% in 2017–2019 and increased from 8.6% to 11.9% after RC surgery. In 2011–2013, male sex, ASA ≥3, (yp)T3-4, neoadjuvant therapy, emergency surgery and multivisceral resection were identified as risk factors for AL after CC surgery. In 2017–2019, only male sex and ASA ≥3 were risk factors for AL. For RC patients, male sex and neoadjuvant therapy were a risk factor for AL in 2011–2013. In 2017–2019, transanal approach was also a risk factor for AL. Postoperative mortality rate after AL was 12% (CC) and 2% (RC) in 2017–2019, without significant changes over time.

Conclusion: Contradictory trends in incidence and mortality for AL were observed among CC and RC surgery with changing risk factors over the past 9 years. High mortality after AL is only observed after CC surgery and remains unchanged. Continued efforts should be made to improve early detection and treatment of AL for these patients.

KEYWORDS
anastomotic leakage, colorectal cancer, risk factor

INTRODUCTION

Colorectal cancer (CRC) is the fourth most common cancer worldwide [1]. The cornerstone of CRC treatment is surgical resection with tumour removal and restoring continuity by constructing an anastomosis. Anastomotic leakage (AL) is a feared postoperative complication and the incidence varies between 1% and 20% [2–4]. AL often requires reintervention and is associated with prolonged
hospitalization, severe morbidity and increased mortality rates [5–8].

Over the years, multiple (surgical) treatment strategies have evolved that might have influenced the incidence, risk factors and clinical impact of AL. Traditionally, CRC was resected using midline laparotomy, but more recently a shift was made towards minimally invasive surgery, which led to shorter hospitalisation, faster postoperative recovery and decreased mortality rates [9, 10]. In addition, the construction of a defunctioning ileostomy to prevent complications from AL after TME surgery has been under debate. Although it decreases the severity of AL, there are evident disadvantages and the preventive effect of defunctioning stomas is ambiguous [9–13]. As a consequence, in the Netherlands, defunctioning stoma construction after RC resection decreased from 51.3% in 2011 to 40% in 2016 [14]. Concomitantly, the number of patients with a primary anastomosis increased as a result of the decline in Hartmann’s procedures [14]. Another modification in the treatment strategy of RC patients was the use of neoadjuvant radiotherapy. Previously, 80% of the Dutch patients were irradiated preoperatively. Despite these high radiation rates, local recurrence rates were comparable to European countries using less preoperative radiation [15, 16]. Therefore, the national guidelines were revised and recommended more restrictive use of neoadjuvant radiotherapy. A recent study showed that as a result a decrease in radiotherapy was observed in the Netherlands while maintaining similar local recurrence rates [17]. With the introduction of the CRC screening program in 2014, patient characteristics have also changed. Screen-detected patients were younger, had fewer comorbidities, and were associated with lower risk of postoperative complications [18].

The majority of the previously published risk factor studies included patients that had been operated upon more than a decade ago. Given the numerous changes in CRC care that might have affected the occurrence and consequences of AL, this study aimed to update the incidence, risk profile, and mortality from AL requiring reintervention during the period 2011–2019 based on data from the Dutch Colorectal Audit (DCRA).

METHODS

Data was retrieved from the DCRA, a nationwide audit that annually collects data on patient, tumour, and treatment characteristics, in-hospital and postoperative outcomes of patients undergoing resection of primary CRC in the Netherlands. This is a mandatory registry in which all hospitals participate.

Patients

No ethical approval or informed consent was required under Dutch law. All patients undergoing CRC resection with primary anastomosis between January 2011 and January 2020 were evaluated. Minimal data requirement for inclusion was information on the type of surgical resection and the presence of an anastomosis. Patients were excluded if they underwent abdominoperineal resection, Hartmann’s procedure, total proctocolectomy or had a tumour located in the appendix. In total, 70,229 patients were included (Figure 1).

Outcomes

The primary outcome in this study was AL, defined as requiring reintervention. Reintervention could consist of surgical, radiological or endoscopic reintervention within 30 days (2011–2017) or 90 days after resection (2018–2019). Since 2018, the DCRA also registers AL that did not require any type of reintervention, but these data are not available for the preceding years. Therefore, AL patients in 2018–2019 that did not require any type of reintervention (N = 67) were excluded. The following variables were extracted from the DCRA registry: patient characteristics (gender, age, ASA, BMI, history of abdominal surgery), tumour characteristics (preoperative tumour complications, location, cancer stage), treatment characteristics (neoadjuvant therapy, urgency of surgery, surgical approach, type of resection, defunctioning stoma construction, multivisceral resection), and postoperative outcomes (AL, length of hospital stay (LOS), postoperative mortality).

Statistics

All patients were divided into three cohorts based on year of resection: 2011–2013, 2014–2016 and 2017–2019. Analyses were stratified for colon cancer (CC) and rectal cancer (RC), and outcomes were compared between AL and non-AL patients. Categorical variables were described by frequencies and percentages. Continuous, non-normally distributed variables are described as median with interquartile range (IQR). Univariable analysis was performed to assess the association of potential risk factors with AL using a X² test. To detect changes of patient, tumour, and treatment characteristics over time, a comparison was made between the eldest and most recent time cohort (2011–2013 vs. 2017–2019) using chi-square test for categorical variables and Mann-Whitney U test for (non-normally distributed) continuous variables. Trends in incidence of AL and postoperative mortality over time were assessed using logistic regression with operation year as continuous variable. To identify risk factors for AL, variables that reached statistical significance in the univariable analysis or with clinical relevance were included in the multivariable regression. Results are displayed by
odds ratios (OR) and 95% confidence intervals (CI), with AL as dependent variable. A p-value <0.05 was considered statistically significant. All analyses were performed in SPSS v25.

RESULTS

Baseline characteristics

Between 1 January 2011 and 1 January 2020, 56,503 CC patients and 13,726 RC patients underwent surgical resection with primary anastomosis (Table 1). When comparing cohort 2011–2013 to 2017–2019, CC and RC patients treated in 2017–2019 were significantly more likely to have an ASA score of ≥3 and a BMI ≥30. There has been a shift towards more restrictive use of neoadjuvant radiotherapy for RC patients, with 66% receiving neoadjuvant radiotherapy in 2011–2013 and 26% in 2017–2019. Emergency resection of CC decreased from 14% (2011–2013) to 7% (2017–2019). For both CC and RC patients, there has been a shift towards minimally invasive surgery, accounting for 86% and 94% of the patients in 2017–2019, respectively. Application of TaTME increased to 13% in 2017–2019. Defunctioning stoma creation decreased, from 68% to 34% after RC resection and from 4% to 1% after CC resection in 2011–2013 and 2017–2019, respectively. However, defunctioning stoma creation increased for TaTME patients from 49% (2014–2016) to 57% (2017–2019). Median LOS of CC patients decreased significantly, from seven (IQR 5–11) to five days (IQR 3–7). For RC patients, LOS significantly decreased from eight (IQR 5–13) to five days (IQR 4–8).

Anastomotic leakage

Over the years, the incidence of AL decreased for CC patients from 6.6% to 4.5% in 2017–2019 (OR 0.68, 95% CI: 0.62–0.74; p < 0.01). For RC patients, the incidence increased from 8.6% to 11.4% in 2017–2019 (OR 1.38, 95% CI: 1.19–1.59; p < 0.01, Figure 2). In 2017–2019, median time until reintervention for AL was 6 days (IQR 3–10) in CC patients and 8 days (IQR 4–15) in RC patients, without significant changes over the years. Stoma creation rate at reoperation for AL did not change for CC patients, and was 73% in 2017–2019. Of these patients, 35% received a defunctioning stoma, and 65% an end stoma. In contrast, stoma creation rate at reoperation for AL increased significantly for RC patients from 50% (2011–2013) to 70% (2017–2019), which is related to the decrease in defunctioning stomas during primary surgery. Fifty-eight percent of these patients received a defunctioning stoma and 42% an end stoma. Median LOS in CC patients with AL decreased from 22 (IQR 14–34, 2011–2013) to 18 days (IQR 11–28, 2017–2019, p = 0.00). For RC patients, a similar reduction in LOS was found: 20 (IQR 9–31) to 15 days (IQR 7–24) (p < 0.01).

Risk factors associated with AL

For CC patients in 2011–2013, multivariable analysis revealed male sex, ASA ≥3, neoadjuvant therapy, emergency surgery, multi-visceral resection, and (yp)T3-4 to be independently associated with an increased AL risk (Figure 3). Age of 70 years and older was demonstrated to be associated with a lower AL risk (OR 0.85, 95% CI:
TABLE 1 Baseline patient-, tumour-, and treatment characteristics per cohort

|                          | 2011–2013 | 2014–2016 | 2017–2019 |
|--------------------------|-----------|-----------|-----------|
|                          | Total (N) | AL (N)    | Total (N) | AL (N)    | Total (N) | AL (N)    |
|                          | N (%)     | N (%)     | N (%)     | N (%)     | N (%)     | N (%)     |
| Gender                   |           |           |           |           |           |           |
| Male                     | 8,812     | 682 (7.7) | 11,300    | 667 (5.9) | 9,189     | 507 (5.5) |
| Female                   | 8,175     | 433 (5.3) | 9,857     | 432 (4.4) | 8,783     | 308 (3.5) |
| Age                      |           |           |           |           |           |           |
| <70                      | 7,334     | 520 (7.1) | 10,006    | 509 (5.1) | 7,659     | 358 (4.7) |
| ≥70                      | 9,697     | 598 (6.2) | 11,259    | 597 (5.3) | 10,372    | 460 (4.4) |
| ASA                      |           |           |           |           |           |           |
| I                        | 3,243     | 188 (5.8) | 3,710     | 156 (4.2) | 2,279     | 81 (3.6)  |
| II                       | 9,705     | 622 (6.4) | 12,672    | 598 (4.7) | 10,312    | 426 (4.3) |
| ≥III+                    | 4,084     | 310 (7.6) | 4,965     | 354 (7.1) | 5,484     | 315 (5.7) |
| BMI (kg/m2)              |           |           |           |           |           |           |
| <18.5                    | 293       | 30 (10.2) | 310       | 16 (5.2)  | 288       | 16 (5.6)  |
| 18.5–24.9                | 6,682     | 426 (6.4) | 7,895     | 409 (5.2) | 6,941     | 296 (4.3) |
| 25.0–29.9                | 6,554     | 431 (6.6) | 8,431     | 426 (5.0) | 7,001     | 315 (4.5) |
| ≥30.0                    | 2,655     | 174 (6.6) | 4,166     | 234 (5.6) | 3,540     | 185 (5.2) |
| History of abdominal     |           |           |           |           |           |           |
| surgery                  |           |           |           |           |           |           |
| No                       | 13,447    | 868 (6.5) | 14,295    | 737 (5.2) | 15,593    | 686 (4.4) |
| Yes                      | 3,627     | 254 (7.0) | 7,059     | 371 (5.3) | 2,477     | 136 (5.5) |
| Preoperative tumour      |           |           |           |           |           |           |
| complications            |           |           |           |           |           |           |
| No                       | 10,179    | 604 (5.9) | 14,724    | 724 (4.9) | 12,176    | 506 (4.2) |
| Yes                      | 6,895     | 518 (7.5) | 6,582     | 383 (5.8) | 5,881     | 316 (5.4) |
| Pathological T           |           |           |           |           |           |           |
| Classification           |           |           |           |           |           |           |
| (y)pT0-2                 | 3,939     | 201 (5.1) | 6,657     | 288 (4.3) | 697       | 211 (3.7) |
| (y)pT3-4                 | 12,884    | 908 (7.0) | 14,606    | 819 (5.6) | 12,096    | 603 (5.0) |
| Pathological N           |           |           |           |           |           |           |
| Classification           |           |           |           |           |           |           |
| pN0                      | 9,873     | 636 (6.4) | 13,106    | 662 (5.1) | 10,992    | 491 (4.5) |
| pN1-2                    | 7,063     | 478 (6.8) | 8,179     | 444 (5.4) | 6,788     | 319 (4.7) |
| Metastatic disease       |           |           |           |           |           |           |
| No                       | 13,822    | 890 (6.4) | 18,871    | 934 (5.0) | 9,582     | 445 (4.6) |
| Yes                      | 1,199     | 141 (7.3) | 1,783     | 139 (7.8) | 1,223     | 74 (6.1)  |
| Neoadjuvant therapy      |           |           |           |           |           |           |
| No neoadjuvant therapy   | 16,728    | 1083 (6.5)| 20,960    | 1070 (5.1)| 17,530    | 786 (4.5) |
| Neoadjuvant chemotherapy | 265       | 30 (11.3) | 323       | 30 (9.3)  | 359       | 24 (6.7)  |
| Neoadjuvant (short-course) radiotherapy | 51 | 6 (11.8) | 40 | 4 (10.0) | 26 | 2 (7.7) |
| Neoadjuvant chemoradiation | 30 | 3 (10.0) | 31 | 4 (12.9) | 27 | 2 (7.4) |
| Timing of surgery        |           |           |           |           |           |           |
| Elective                 | 14,658    | 909 (6.2) | 19,503    | 973 (5.0) | 16,789    | 741 (4.4) |
| Emergency                | 2,405     | 213 (8.9) | 1,844     | 135 (7.3) | 1,277     | 81 (6.3)  |
| Surgical approach        |           |           |           |           |           |           |
| Open surgery             | 8,292     | 595 (7.2) | 5,202     | 372 (7.2) | 2,317     | 159 (6.9) |
| Laparoscopic surgery with conversion | 1,168 | 98 (8.4) | 1,765 | 129 (7.3) | 1,437 | 105 (7.3) |
| Laparoscopic surgery without conversion | 7,174 | 409 (5.7) | 14,028 | 587 (4.2) | 12,735 | 495 (3.9) |
| TaTME                     |           |           |           |           |           |           |
| Robot-assisted surgery   | -         | -         | -         | -         | -         | 596       | 20 (3.4) |
### TABLE 1
Baseline patient-, tumour- , and treatment characteristics per cohort

|                  | 2011–2013 | 2014–2016 | 2017–2019 |
|------------------|-----------|-----------|-----------|
| Surgical approach| Open surgery | Elective | Neoadjuvant |
|                  | Total (N) | N (%)     | Total (N)  | N (%)     | Total (N)  | N (%)     |
|                  | 3,840     | 217 (9.2) | 5,067      | 466       | 4,819      | 550       |
|                  | N (%)     | 2,354     | 3,207      | 345 (10.8) | 2,954      | 399 (13.5) |
|                  |           | 1,477     | 1,830      | 117 (6.4)  | 1,858      | 150 (8.1)  |
|                  |           | 2,455     | 3,297      | 319 (9.7)  | 3,019      | 368 (12.2) |
|                  |           | 1,383     | 1,754      | 145 (8.3)  | 1,795      | 181 (10.1) |
|                  |           | 1,152     | 1,289      | 116 (9.0)  | 898        | 94 (10.5)  |
|                  |           | 2,230     | 3,157      | 293 (9.3)  | 3,116      | 349 (11.2) |
|                  |           | 456       | 621        | 57 (9.2)   | 805        | 107 (13.3) |
|                  |           | 53        | 57         | 4 (7.0)    | 61         | 10 (16.4)  |
|                  |           | 1,599     | 1,946      | 173 (8.9)  | 1,926      | 209 (10.9) |
|                  |           | 1,569     | 2,136      | 210 (9.9)  | 1,935      | 217 (11.2) |
|                  |           | 525       | 818        | 71 (8.7)   | 820        | 105 (12.8) |
|                  |           | 3,127     | 3,711      | 367 (9.9)  | 4,306      | 497 (11.5) |
|                  |           | 713       | 843        | 99 (7.3)   | 513        | 53 (10.3)  |
|                  |           | 2,893     | 4,219      | 377 (8.9)  | 4,318      | 487 (11.3) |
|                  |           | 947       | 75 (7.9)   | 4 (10.6)   | 496        | 63 (12.7)  |
|                  |           | 1,773     | 2,574      | 225 (8.7)  | 2,389      | 282 (11.8) |
|                  |           | 2,001     | 2,445      | 238 (9.7)  | 2,306      | 253 (11.0) |
|                  |           | 2,444     | 3,371      | 289 (8.6)  | 2,972      | 341 (11.5) |
|                  |           | 1,369     | 1,681      | 175 (10.4) | 1,760      | 202 (11.5) |
|                  |           | 3,430     | 4,696      | 427 (9.1)  | 2,669      | 285 (10.7) |
|                  |           | 207       | 246        | 26 (10.6)  | 275        | 26 (9.5)   |
|                  |           | 702       | 2,310      | 214 (9.3)  | 2,659      | 266 (10.0) |
|                  |           | 27        | 24         | 2 (8.3)    | 53         | 3 (5.7)    |
|                  |           | 2,520     | 2,094      | 186 (8.9)  | 1,269      | 172 (13.6) |
|                  |           | 591       | 639        | 64 (10.0)  | 817        | 108 (13.2) |
|                  |           | 3,806     | 5,039      | 461 (9.1)  | 4,778      | 545 (11.4) |
|                  |           | 29        | 28         | 5 (17.9)   | 40         | 5 (12.5)   |
|                  |           | 1,433     | 639        | 48 (7.5)   | 258        | 27 (10.5)  |
|                  |           | 297       | 339        | 28 (8.3)   | 186        | 24 (12.9)  |
|                  |           | 1,967     | 3,772      | 365 (9.7)  | 2,976      | 306 (10.3) |
|                  |           | 23        | 238        | 22 (9.2)   | 633        | 111 (17.5) |
|                  |           |           |           |           |           |           |

(Note: Some values are rounded for presentation purposes.)
In 2017–2019, only male sex and ASA ≥3 were identified as independent risk factors for AL. Conventional laparoscopic surgery (excluding TaTME) was associated with a significantly lower AL risk compared to open surgery (OR 0.60, 95% CI: 0.46–0.79). Treatment period also remained associated with AL in multivariable analysis, with a lower risk in 2017–2019 (AOR 0.68, 95% CI: 0.62–0.74).

Treatment period remained associated with AL after RC surgery after correction for confounders, with a higher risk for patients treated between 2017–2019 (AOR 1.38, 95% CI: 1.19–1.59).

Compared to 2011–2013, overall postoperative mortality was significantly lower for CC patients in 2017–2019 (3.3%–2.0%, AOR 0.58, 95% CI: 0.52–0.67, Figure 4). A similar reduction was found for RC patients (1.5%–0.8%, AOR 0.52, 95% CI: 0.35–0.79). During the whole study period (2011–2019), AL was associated with a significantly higher overall postoperative mortality compared to non-AL patients for both CC and RC. Postoperative mortality rate in CC patients with AL remained high over the years, and was 11% in 2017–2019. In RC patients, the postoperative mortality rate after AL did not significantly change over the years and was 3% in 2017–2019. Multivariable analysis identified ASA ≥3 and age ≥70 years as risk factors for postoperative mortality in 2017–2019 for CC patients with AL, without changes over the years. For RC patients, only age ≥70 years was a risk factor for postoperative mortality.
in 2011–2013 (OR 5.9, 95% CI: 1.57–22.09). In 2017–2019, age ≥70 years, ASA ≥3 and preoperative tumour complications were risk factors for postoperative mortality after AL.

**DISCUSSION**

This population-based study provides trends in incidence, risk factors, and postoperative mortality for AL after CRC resection throughout 9 years of auditing in the Netherlands. We demonstrated a significant decrease in incidence of AL after CC resection, while the incidence of AL after RC resection significantly increased over the years. Risk profiles for AL changed over the years. Whereas many risk factors were identified for AL after CC resection in 2011–2013, only male sex and ASA ≥3 were identified in 2017–2019. In RC patients, male sex and neoadjuvant radiotherapy were risk factors throughout the years and TaTME was identified as new risk factor for AL in 2017–2019. Interestingly, a defunctioning stoma was identified as protective for AL after RC resection in all consecutive cohorts. In addition, postoperative mortality after colonic AL was persistently high while substantially lower rates were found for RC patients, and these rates did not change over time.

The incidence of AL after RC surgery increased significantly over the past nine years, with the largest increase between 2017–2018 (10.6%–13.1%). Although the overall AL rate is in line with literature, the increase is noteworthy [2, 19]. There are several explanations. First, there has been a reduction in defunctioning stoma construction at primary surgery. Defunctioning stomas were identified as a protective factor, however, fewer patients received a stoma and as a consequence the AL rate increased. Second, another contributing factor may be the implementation and increased application of TaTME since 2012. TaTME is mainly performed for distal RC and was introduced to overcome the difficulties of conventional laparoscopic TME. However, TaTME is difficult to learn and in order to pass the learning curve and reduce postoperative complications, high case-volumes are necessary [20, 21]. Dettering et al. concluded that three centres in the Netherlands surpassed the threshold for the learning curve of 40 cases/year. Moreover, while there are 44 Dutch hospitals performing TaTME, only fifteen finalized the training programme. Although a comparison between trained and untrained centers was not possible [22], it is reasonable to assume that low case-volume centres contributed to higher AL rates. Therefore, we expect that TaTME operations will be centralized in expert centers in the future. This might cause a reduction of overall TaTME cases, but could also contribute to a reduction of postoperative complications. In a recent nationwide study of Rutgers et al., TaTME was associated with higher AL rates than conventional laparoscopic TME of a tumour <5 cm from the anorectal junction (15.9% vs. 12.8%, p < 0.01) [23]. This study also identified TaTME as risk factor for AL with an absolute 18% leak rate in 2017–2019. While defunctioning stoma construction after RC resection decreased over the years, the number of defunctioning stomas in TaTME patients increased from 49% (2014–2016) to 57% (2017–2019). Although defunctioning stomas were a protective factor for AL throughout the years in the total RC population, this phenomenon is not seen in TaTME patients.
Adjusted multivariable analysis revealed several risk factors for AL for both CC and RC patients. Consistent with literature, male sex was an independent risk factor for AL in both CC and RC patients [24–26]. Although the increased risk for men undergoing RC resection might be related to the narrow pelvis, which can complicate restoration of bowel continuity, this is not applicable to CC resections [27]. Another explanation might be the fact that androgens inhibit the endothelial function, which can negatively affect anastomotic healing [28]. Besides, for CC patients, higher ASA classification (≥3) was identified as a risk factor for AL. ASA classification is a reflection of the patients’ comorbidities and was identified as a risk factor for colonic AL in a previous nationwide study [29]. Furthermore, this study suggests that surgical approach is related with the risk of AL. Conventional laparoscopy protects for AL, which is in line with previous studies. In contrast, both open and converted surgery were associated with an increased AL risk after CC surgery. Case selection can be an explanation for these findings. Compared to laparoscopic surgery, patients undergoing open surgery have more comorbidities and are obese [30, 31]. These are also risk factors for AL [29, 32, 33]. In addition, patients that are preoperatively assigned to open surgery are usually expected to have intraabdominal adhesions, which may complicate surgery with an increased AL risk as a consequence. In case of conversion, there is inability to correctly visualize the anatomy, intraoperative complications have developed or intraabdominal adhesions are detected. Therefore, technical difficulties during the surgical procedure may have increased the risk of AL. With the introduction of minimally invasive techniques the surgical practice has been optimized. Robot-assisted laparoscopic surgery might be beneficial for more challenging surgical pathologies. Whether robotic surgery will become the preferred modality in the upcoming...
years is debated due to lacking evidence regarding cost effectiveness and long-term oncological outcomes [34]. During the past nine years, there has been a decline in the use of neoadjuvant therapy. Nevertheless, neoadjuvant therapy is still a risk factor for AL after RC resection [3]. Finally, this study confirms the generally found association between defunctioning stoma and lower risk of AL [9–12]. However, this does not necessarily mean that a stoma is protective for the occurrence of AL, as illustrated by studies with long term follow-up that include the late leakages that might even become apparent after closure of the defunctioning stoma [2].

In line with previous studies, a difference between mortality rates after CC and RC surgery was found [29, 33]. This can be explained by the location of the anastomosis. CC patients are at higher risk of generalized peritonitis with a relatively high risk of mortality, because of the intraperitoneally located anastomosis. In contrast, RC patients with AL often have sealed-off leakage at the level of the pelvic inlet. These leaks often result in extraperitoneal abscess formation and rarely result in ‘failure to rescue’. In this study, postoperative mortality rate among colonic AL patients remained high over the years. This is in line with previous published European cohorts that presented postoperative mortality rates varying between
16%–29% [6, 35–37]. Although these mortality rates are higher compared to our 2017–2019 cohort, there is room for improvement. Early detection and more aggressive treatment modalities for AL in CC patients to prevent postoperative mortality should be a priority. Den Dulk et al. developed the DULK-score in 2014, a clinical diagnostic tool for early detection of AL based on clinical parameters, physical examination, laboratory investigation and nutritional status [38]. Although the DULK score can detect AL almost four days ahead of clinical judgement, it is not widely implemented and apparently did not affect mortality rates [39]. The persisting high mortality rates after colonic AL warrants further studies to explore potential diagnostic tools or interventions that can reduce the failure to rescue rate.

This study was strengthened by the inclusion of all patients that underwent CRC surgery in Dutch hospitals during 2011–2019. By analysing data of nine years, trends in risk factors, incidence and mortality from AL after CC and RC surgery were identified. Although almost all data was complete, it is inevitable that there is still a minor degree of incomplete data. However, this is not expected to bias the results. AL was defined as requiring any type of reintervention, therefore, conclusions for grade A leakages cannot be drawn. However, the most important limitation lies in the fact that the DCRA has a limited follow-up. Before 2018, the DCRA registered 30-day outcomes and it started registering 90-day outcomes in 2018. Since the majority of the patients underwent surgery before 2018, this study excludes information about late ALs and the related mortality. Borstlap et al. concluded that approximately one third of the patients with a defunctioning stoma develop AL after 30 days [2]. In this study, the majority of the RC patients operated before 2018 received a defunctioning stoma (68% in 2011–2013 and 53% in 2014–2016) and we observed a decline in construction of defunctioning stomas in 2017–2019 (34%). Therefore, the incidence of AL may have been underestimated in this study between 2011 and 2017. Reporting 90-day outcomes in 2017–2019 may have led to a better reflection of the true incidence of AL.

In conclusion, this study demonstrates that, throughout the past 9 years, changes in population characteristics led to a different incidence, risk profile and mortality from AL. Clinicians should be aware of these changes and adjust patient counselling accordingly. Further research should focus on the early detection of AL after CC resection with optimized management to reduce postoperative mortality.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Melissa Arron, Nynke Greijdanus, Pieter Tanis and Hans de Wilt contributed to the conception of the study. Melissa Arron and Nynke Greijdanus performed the data analysis and manuscript preparation. All authors reviewed the final manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

No ethical approval or informed consent was required under Dutch law.

ORCID

Pieter J. Tanis https://orcid.org/0000-0002-3146-3310

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Borstlap WAA, Westerduin E, Aukema TS, Beemelman WA, Tanis PJ. Anastomotic leakage and chronic presacral sinus formation after low anterior resection: results from a large cross-sectional study. Ann Surg. 2017;266(5):870–7.
3. Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Risk factors of anastomotic leakage and long-term survival after colorectal surgery. Medicine. 2016;95(8):e2890-e.
4. Telem DA, Chin EH, Nguyen SQ, Divino CM. Risk factors for anastomotic leak following colorectal surgery: a case-control study. Arch Surg. 2010;145(4):371–6.
5. Koedam TWA, Bootsmma BT, Deijen CL, van de Brug T, Kazemier G, Cuesta MA, et al. Oncological outcomes after anastomotic leakage after surgery for colon or rectal cancer: increased risk of local recurrence. Ann Surg. 2020.
6. Krarup PM, Nordholm-Carstensen A, Jorgensen LN, Harling H. Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg. 2014;259(5):930–8.
7. Boström P, Haapamäki MM, Rutegård J, Matthiessen P, Rutegård M. Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer. BJU Open. 2018;3(1):106–11.
8. Turrentine FE, Denlinger CE, Simpson VB, Garwood RA, Guerlain S, Agrawal A, et al. Morbidity, mortality, cost, and survival estimates of gastrointestinal anastomotic leaks. J Am Coll Surg. 2015;220(2):195–206.
9. Phan K, Oh L, Ctercteko G, Pathma-Nathan N, El Khoury T, Azam H, et al. Does a stoma reduce the risk of anastomotic leak and need for re-operation following low anterior resection for rectal cancer: systematic review and meta-analysis of randomized controlled trials. J Gastrointest Oncol. 2019;10(2):179–87.
10. Matthiessen P, Halliböök O, Rutegård J, Simert G, Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg. 2007;246(2):207–14.
11. Snijders HS, van den Broek C, Wouters M, Meershoek-Klein Kranenburg E, Wiggers T, Rutten H, et al. An increasing use of defunctioning stomas after low anterior resection for rectal cancer. Is this the way to go? Eur J Surg Oncol. 2013;39(7):715–20.
12. Hüser N, Michalski CW, Erkan M, Schuster T, Rosenberg K, Kleeff J, et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg. 2008;248(1):52–60.
13. Saha AK, Tapping CR, Foley GT, Baker RP, Sagar PM, Burke DA, et al. Morbidity and mortality after closure of loop ileostomy. Colorectal Dis. 2009;11(8):866–71.
14. de Neree tot Babberich MPM, Detering R, Dekker JWT, Elferink MA, Tollenaar RAEM, Wouters MWJM, et al. Achievements in colorectal cancer care during 8 years of auditing in The Netherlands. Eur J Surg Oncol. 2018;44(9):1361–70.
15. van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenburg E-K, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total
mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.

16. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.

17. Koëter T, Elferink MA, Verhoeven R, Zimmerman D, Wasowicz DK, Verheij M, et al. Hospital variance in neoadjuvant rectal cancer treatment and the influence of a national guideline update: Results of a five-year nationwide population-based study. Radiother Oncol. 2020;145:162–71.

18. de Neree tot Babberich MPM, Vermeer NCA, Wouters MWJM, van Grevenstein WMU, Peeters KCJM, Dekker E, et al. Postoperative outcomes of screen-detected vs non-screen-detected colorectal cancer in the Netherlands. JAMA Surgery. 2018;153(12):e183567.

19. Jannasch O, Klinge T, Otto R, Chiapponi C, Udelnow A, Lippert H, et al. Risk factors, short and long term outcomes of anastomotic leaks in rectal cancer. Oncotarget. 2015;6(34):36884–93.

20. Koedam TWA, Veltcamp Helbach M, van de Ven PM, Kruyt PM, van Heek NT, Bonjer HJ, et al. Transanal total mesorectal excision for rectal cancer: evaluation of the learning curve. Tech Coloproctol. 2018;22(4):279–87.

21. Persiani R, Agnes A, Belia F, D’Ugo D, Biondi A. The learning curve of TaTME for mid-low rectal cancer: a comprehensive analysis from a five-year institutional experience. Surg Endosc. 2020.

22. Detering R, Rooibeek SX, van Oostendorp SE, Dekker JT, Siethes C, Bemelman WA, et al. Three-year nationwide experience with transanal total mesorectal excision for rectal cancer in the Netherlands: a propensity score-matched comparison with conventional laparoscopic total mesorectal excision. J Am Coll Surg. 2019;228(3):235–44.e1.

23. Rutgers ML, Detering R, Rooibeek SX, Crolla RM, Dekker JWT, Tuynman JB, et al. Influence of minimally invasive resection technique on sphincter preservation and short- term outcome in low rectal cancer in the Netherlands. Dis Colon Rectum. 2021.

24. Frasson M, Granero-Castro P, Ramos Rodríguez JL, Flor-Lorette B, Braithwaite M, Martí Martínez E, et al. Risk factors for anastomotic leak and postoperative morbidity and mortality after elective right colectomy for cancer: results from a prospective, multicentric study of 1102 patients. Int J Colorectal Dis. 2016;31(1):105–14.

25. Suding P, Jensen E, Abramson MA, Itani K, Wilson SE. Definitive risk factors for anastomotic leaks in elective open colorectal resection. Arch Surg. 2008;143(9):907–12.

26. McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg. 2015;102(5):462–79.

27. Law WL, Chu KW, Ho JWC, Chan C-W. Risk factors for anastomotic leakage after low anterior resection with total mesorectal excision. Am J Surg. 2000;179(2):92–6.

28. Ba ZF, Yokoyama Y, Toth B, Rue LW 3rd, Bland KI, Chaudry IH. Gender differences in small intestinal endothelial function: inhibitory role of androgens. Am J Physiol Gastrointest Liver Physiol. 2004;286(3):G452–7.